{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T15:41:10Z","timestamp":1775662870589,"version":"3.50.1"},"reference-count":50,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["Indian J Dermatol Venereol Leprol"],"abstract":"<jats:p>Cutaneous T-cell lymphoma is a heterogeneous group of T-cell neoplasms, of which mycosis fungoides and Sezary syndrome are the most common. The prognosis depends on the stage of the disease. The early stage follows a protracted course with a five-year disease-specific survival of greater than 95% and is treated with skin-directed topical therapies, phototherapy, and oral drugs like methotrexate. Advanced disease has a five-year overall survival of less than 25% and requires management by systemic chemotherapeutic agents. This review article is the second part out of the two covering the staging, prognosis, and treatment from a dermatologist\u2019s perspective.<\/jats:p>","DOI":"10.25259\/ijdvl_754_2023","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T07:46:28Z","timestamp":1733384788000},"page":"180-187","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mycosis fungoides and Sezary syndrome \u2013 Simplifying the approach for dermatologists. Part 2: Evaluation, staging, prognosis and treatment"],"prefix":"10.25259","volume":"91","author":[{"given":"Gautam Kumar","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Dermatology, Bharati Vidyapeeth\u2019s Medical College, Pune, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pankaj","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Armed Forces Medical College, Pune, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shailendra","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Base Hospital Delhi Cantonment and Army College of Medical Sciences, Delhi Cantt, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanwaljeet","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Pathology, Army Hospital, Research and Referral, Kolkata, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikram","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of  Pathology, Armed Forces Medical College, Pune, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanghita","family":"Barui","sequence":"additional","affiliation":[{"name":"Department of Pathology, Base Hospital, Delhi Cantonment and Army College of Medical Sciences, Delhi Cantt, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Mulajkar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Army Hospital Research and Referral, Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indra Prakash","family":"Dubey","sequence":"additional","affiliation":[{"name":"Department of Nuclear Imaging, Army Hospital Research and Referral, Delhi, India,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2024,11,4]]},"reference":[{"key":"10.25259\/IJDVL_754_2023\/ref-1","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1001\/archderm.144.6.738","article-title":"Folliculotropic mycosis fungoides: An aggressive variant of cutaneous T-cell lymphoma","volume":"144","author":"Gerami","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.25259\/IJDVL_754_2023\/ref-3","first-page":"725","article-title":"Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas","volume":"63","author":"Bunn","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"10.25259\/IJDVL_754_2023\/ref-4","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1097\/PAT.0000000000000166","article-title":"Mycosis fungoides with large cell transformation: Clinicopathological features and prognostic factors","volume":"46","author":"Pulitzer","year":"2014","journal-title":"Pathology"},{"key":"10.25259\/IJDVL_754_2023\/ref-5","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood, The Journal of the American Society of Hematology"},{"key":"10.25259\/IJDVL_754_2023\/ref-6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/1097-0142(19800101)45:1<137::aid-cncr2820450124>3.0.co;2-k","article-title":"Dermatopathic lymphadenopathy and lymph node involvement in mycosis fungoides","volume":"45","author":"Scheffer","year":"1980","journal-title":"Cancer"},{"key":"10.25259\/IJDVL_754_2023\/ref-7","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin\u2019s disease: Cotswolds meeting","volume":"7","author":"Lister","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.25259\/IJDVL_754_2023\/ref-8","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organisation of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"10.25259\/IJDVL_754_2023\/ref-9","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1016\/j.ejca.2013.04.018","article-title":"A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome","volume":"49","author":"Benton","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.25259\/IJDVL_754_2023\/ref-10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113343","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/Sezary syndrome \u2013 Update 2023","volume":"195","author":"Latzka","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.25259\/IJDVL_754_2023\/ref-11","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1001\/archderm.1996.03890350051009","article-title":"Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis","volume":"132","author":"Kim","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.25259\/IJDVL_754_2023\/ref-12","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1001\/archderm.134.8.949","article-title":"Topical corticosteroids for mycosis fungoides. Experience in 79 patients","volume":"134","author":"Zackheim","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.25259\/IJDVL_754_2023\/ref-13","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archderm.139.2.165","article-title":"Topical nitrogen mustard in the management of mycosis fungoides: Update of the Stanford experience","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.25259\/IJDVL_754_2023\/ref-14","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/bjd.12620","article-title":"Secondary cancers, comorbidities and mortality associated with nitrogen mustard therapy in patients with mycosis fungoides: A 30-year population-based cohort study","volume":"170","author":"Lindahl","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_754_2023\/ref-15","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.1396-0296.2003.01640.x","article-title":"Management with topical nitrogen mustard in mycosis fungoides","volume":"16","author":"Kim","year":"2003","journal-title":"Dermatol Ther"},{"key":"10.25259\/IJDVL_754_2023\/ref-17","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1159\/000516138","article-title":"Post hoc analysis of a randomized, controlled, phase 2 study to assess response rates with chlormethine\/mechlorethamine gel in patients with stage IA\u2013IIA mycosis fungoides","volume":"238","author":"Querfeld","year":"2022","journal-title":"Dermatology"},{"key":"10.25259\/IJDVL_754_2023\/ref-18","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1396-0296.2003.01641.x","article-title":"Topical carmustine (BCNU) in the treatment of mycosis fungoides","volume":"16","author":"Zackheim","year":"2003","journal-title":"Dermatol Ther"},{"key":"10.25259\/IJDVL_754_2023\/ref-19","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1001\/archderm.138.3.325","article-title":"Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma","volume":"138","author":"Breneman","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.25259\/IJDVL_754_2023\/ref-20","first-page":"906","article-title":"Successful treatment of patch type mycosis fungoides with tacrolimus ointment 0.1%","volume":"5","author":"Rallis","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"10.25259\/IJDVL_754_2023\/ref-21","doi-asserted-by":"publisher","first-page":"e425","DOI":"10.1016\/S2352-3026(22)00107-7","article-title":"Activity and safety of topical pimecrolimus in patients with early stage mycosis fungoides (PimTo-MF): A single-arm, multicentre, phase 2 trial","volume":"9","author":"Ortiz-Romero","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.25259\/IJDVL_754_2023\/ref-22","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1080\/09546634.2017.1294728","article-title":"Complete resolution of mycosis fungoides tumors with imiquimod 5% cream: a case series","volume":"28","author":"Lewis","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"10.25259\/IJDVL_754_2023\/ref-23","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1182\/blood-2015-02-630335","article-title":"Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma","volume":"126","author":"Rook","year":"2015","journal-title":"Blood"},{"key":"10.25259\/IJDVL_754_2023\/ref-24","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1001\/jamadermatol.2018.5204","article-title":"Comparison of narrowband UV-B with psoralen-UV-A phototherapy for patients with early-stage mycosis fungoides: A systematic review and meta-analysis","volume":"155","author":"Phan","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.25259\/IJDVL_754_2023\/ref-25","doi-asserted-by":"publisher","first-page":"e92","DOI":"10.1111\/ijd.16050","article-title":"The efficacy of 308-nm excimer laser in the treatment of mycosis fungoides","volume":"62","author":"Sosh","year":"2023","journal-title":"Int J Dermatol"},{"key":"10.25259\/IJDVL_754_2023\/ref-26","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1001\/jamadermatol.2018.5905","article-title":"Evaluation of low-dose, low-frequency oral psoralen-UV-A treatment with or without maintenance on early-stage mycosis fungoides: A randomized clinical trial","volume":"155","author":"Vieyra-Garcia","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.25259\/IJDVL_754_2023\/ref-27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","article-title":"European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/Sezary syndrome \u2013 Update 2017","volume":"77","author":"Trautinger","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.25259\/IJDVL_754_2023\/ref-28","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ijrobp.2015.01.008","article-title":"Modern radiation therapy for primary cutaneous lymphomas: Field and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"92","author":"Specht","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.25259\/IJDVL_754_2023\/ref-29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.rpor.2013.08.003","article-title":"Literature review of clinical results of total skin electron irradiation (TSEBT) of mycosis fungoides in adults","volume":"19","author":"Moraes","year":"2014","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.25259\/IJDVL_754_2023\/ref-30","doi-asserted-by":"publisher","first-page":"e15840","DOI":"10.1111\/dth.15840","article-title":"Short-term efficacy and safety of total skin electron beam therapy in mycosis fungoides: Systematic review and meta-analysis","volume":"35","author":"Grandi","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.25259\/IJDVL_754_2023\/ref-31","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/s0190-9622(03)01591-3","article-title":"Low-dose methotrexate to treat mycosis fungoides: A retrospective study in 69 patients","volume":"49","author":"Zackheim","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_754_2023\/ref-32","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/j.1365-2133.2012.11156.x","article-title":"Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: Final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00: PUVA vs. PUVA and bexarotene for treatment of MF","volume":"167","author":"Whittaker","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_754_2023\/ref-33","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1111\/jdv.14366","article-title":"Dose-escalation study evaluating pegylated interferon alpha-2a in patients with cutaneous T-cell lymphom","volume":"31","author":"Schiller","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_754_2023\/ref-34","doi-asserted-by":"publisher","first-page":"e291","DOI":"10.1111\/jdv.17795","article-title":"The use of pegylated interferon a-2a in a cohort of Greek patients with mycosis fungoides","volume":"36","author":"Patsatsi","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_754_2023\/ref-35","first-page":"943","article-title":"Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen","volume":"23","author":"Peng","year":"2004","journal-title":"Ai Zheng"},{"key":"10.25259\/IJDVL_754_2023\/ref-36","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/bjd.20757","article-title":"Single-centre experience of using pegylated liposomal doxorubicin as maintenance treatment in mycosis fungoides","volume":"186","author":"Falkenhain-L\u00f3pez","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_754_2023\/ref-37","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1159\/000517830","article-title":"Clinical outcomes of advanced-stage cutaneous lymphoma under low-dose gemcitabine treatment: Real-life data from the German cutaneous lymphoma network","volume":"238","author":"Blazejak","year":"2022","journal-title":"Dermatology"},{"key":"10.25259\/IJDVL_754_2023\/ref-38","doi-asserted-by":"publisher","first-page":"e15482","DOI":"10.1111\/dth.15482","article-title":"Continuous low-dose gemcitabine in primary cutaneous T cell lymphoma: A retrospective study","volume":"35","author":"Di Raimondo","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.25259\/IJDVL_754_2023\/ref-39","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s40264-015-0285-9","article-title":"Chimeric fusion proteins used for therapy: Indications, mechanisms, and safety","volume":"38","author":"Baldo","year":"2015","journal-title":"Drug Saf"},{"key":"10.25259\/IJDVL_754_2023\/ref-40","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1200\/JCO.2009.26.2386","article-title":"Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma","volume":"28","author":"Prince","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.25259\/IJDVL_754_2023\/ref-41","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","article-title":"Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma","volume":"19","author":"Olsen","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.25259\/IJDVL_754_2023\/ref-42","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.3109\/10428190903216770","article-title":"Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: A single institution experience from the Robert H. Lurie Comprehensive Cancer Center","volume":"50","author":"Querfeld","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.25259\/IJDVL_754_2023\/ref-43","first-page":"702","article-title":"Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma","volume":"90","author":"Zinzani","year":"2005","journal-title":"Haematologica"},{"key":"10.25259\/IJDVL_754_2023\/ref-44","doi-asserted-by":"publisher","first-page":"5098","DOI":"10.1182\/bloodadvances.2021004710","article-title":"Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician\u2019s choice in cutaneous T-cell lymphoma: Final data","volume":"5","author":"Horwitz","year":"2021","journal-title":"Blood Adv"},{"key":"10.25259\/IJDVL_754_2023\/ref-45","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.25259\/IJDVL_754_2023\/ref-46","doi-asserted-by":"publisher","first-page":"e407","DOI":"10.3324\/haematol.2016.146977","article-title":"European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed\/refractory peripheral T-cell lymphoma","volume":"101","author":"Zinzani","year":"2016","journal-title":"Haematologica."},{"key":"10.25259\/IJDVL_754_2023\/ref-47","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s40257-018-0380-7","article-title":"Current status of HDAC inhibitors in cutaneous T-cell lymphoma","volume":"19","author":"Lopez","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.25259\/IJDVL_754_2023\/ref-48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jdv.12311","article-title":"Guidelines on the use of extracorporeal photopheresis","volume":"28","author":"Knobler","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_754_2023\/ref-49","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/ijd.12121","article-title":"Extracorporeal photopheresis for the treatment of erythrodermic cutaneous T-cell lymphoma: A single center clinical experience with long-term follow-up data and a brief overview of the literature","volume":"52","author":"Quaglino","year":"2013","journal-title":"Int J Dermatol"},{"key":"10.25259\/IJDVL_754_2023\/ref-50","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1001\/archdermatol.2011.232","article-title":"High clinical response rate of Sezary syndrome to immunomodulatory therapies: Prognostic markers of response","volume":"147","author":"Raphael","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.25259\/IJDVL_754_2023\/ref-51","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.det.2015.05.014","article-title":"Hematopoietic stem cell transplant for mycosis fungoides and Sezary syndrome","volume":"33","author":"Virmani","year":"2015","journal-title":"Dermatol Clin"},{"key":"10.25259\/IJDVL_754_2023\/ref-52","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","article-title":"European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/Sezary syndrome \u2013 Update 2017","volume":"77","author":"Trautinger","year":"2017","journal-title":"Eur J Cancer"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/mycosis-fungoides-and-sezary-syndrome-simplifying-the-approach-for-dermatologists-part-2-evaluation-staging-prognosis-and-treatment\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/mycosis-fungoides-and-sezary-syndrome-simplifying-the-approach-for-dermatologists-part-2-evaluation-staging-prognosis-and-treatment\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T11:18:13Z","timestamp":1739963893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/mycosis-fungoides-and-sezary-syndrome-simplifying-the-approach-for-dermatologists-part-2-evaluation-staging-prognosis-and-treatment\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,4]]},"references-count":50,"alternative-id":["10.25259\/IJDVL_754_2023"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_754_2023","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,4]]},"article-number":"180"}}